Genezen is committed to investing in cutting edge technologies to accelerate customers' speed to market. As part of this commitment, Genezen conducted a comparison study between the traditional P24 ELISA method and two novel commercially available technologies for lentiviral titer determination.
Steve Favaloro, President and CEO of Genezen, said, "We are delighted to be presenting the results of our analytical methods evaluation at ASGCT, which demonstrates how our commitment to innovation and a best-in-class process- and analytical development team can reduce time and costs for our customers." He added, "We are also very much looking forward to meeting so many of our customers in person in LA and sharing some of the exciting developments taking place at Genezen."
Genezen will be presenting Poster #981, entitled "Technology Evaluation: Quicker Method for Lentiviral Vector Physical Titer Determination", at 12pm on May 18, 2023, and exhibiting at Booth #641.
